Christopher Raymond
Stock Analyst at Piper Sandler
(3.19)
# 1,132
Out of 4,721 analysts
125
Total ratings
48.54%
Success rate
0.29%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Downgrades: Neutral | $315 → $138 | $153.27 | -9.96% | 19 | Jan 2, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $212 → $220 | $180.10 | +22.15% | 11 | Dec 17, 2024 | |
| QTTB Q32 Bio | Maintains: Overweight | $85 → $20 | $3.66 | +446.45% | 2 | Dec 11, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Overweight | $3 → $13 | $2.53 | +413.83% | 2 | Nov 18, 2024 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $4 → $5 | $0.83 | +503.14% | 4 | Nov 6, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,242 → $1,195 | $716.26 | +66.84% | 6 | Nov 1, 2024 | |
| BHVN Biohaven | Maintains: Overweight | $66 → $76 | $38.87 | +95.52% | 7 | Sep 23, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $107 → $122 | $67.07 | +81.90% | 14 | Sep 5, 2024 | |
| IOBT IO Biotech | Maintains: Overweight | $10 | $0.90 | +1,013.34% | 2 | Sep 3, 2024 | |
| TYRA Tyra Biosciences | Initiates: Overweight | $33 | $16.06 | +105.48% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $500 → $535 | $402.49 | +32.92% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $7 | $2.05 | +241.46% | 2 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $5.00 | +200.00% | 6 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $78 → $104 | $89.54 | +16.15% | 3 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $7.27 | +477.72% | 1 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $21 | $1.79 | +1,073.18% | 5 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $27 → $1.5 | $0.47 | +217.19% | 2 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $130 | $42.66 | +204.74% | 4 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 | $8.06 | +172.95% | 1 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2 → $4 | $1.87 | +113.90% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $25 | $6.34 | +294.32% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $293 → $288 | $258.59 | +11.37% | 16 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $41 | $33.54 | +22.24% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $54.62 | -48.74% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $78.09 | -48.78% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $4.10 | +2,095.12% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $96 | $1.93 | +4,874.09% | 2 | Mar 13, 2020 |
Biogen
Jan 2, 2025
Downgrades: Neutral
Price Target: $315 → $138
Current: $153.27
Upside: -9.96%
AbbVie
Dec 17, 2024
Maintains: Overweight
Price Target: $212 → $220
Current: $180.10
Upside: +22.15%
Q32 Bio
Dec 11, 2024
Maintains: Overweight
Price Target: $85 → $20
Current: $3.66
Upside: +446.45%
Aclaris Therapeutics
Nov 18, 2024
Upgrades: Overweight
Price Target: $3 → $13
Current: $2.53
Upside: +413.83%
Karyopharm Therapeutics
Nov 6, 2024
Maintains: Overweight
Price Target: $4 → $5
Current: $0.83
Upside: +503.14%
Regeneron Pharmaceuticals
Nov 1, 2024
Maintains: Overweight
Price Target: $1,242 → $1,195
Current: $716.26
Upside: +66.84%
Biohaven
Sep 23, 2024
Maintains: Overweight
Price Target: $66 → $76
Current: $38.87
Upside: +95.52%
BioMarin Pharmaceutical
Sep 5, 2024
Maintains: Overweight
Price Target: $107 → $122
Current: $67.07
Upside: +81.90%
IO Biotech
Sep 3, 2024
Maintains: Overweight
Price Target: $10
Current: $0.90
Upside: +1,013.34%
Tyra Biosciences
Aug 15, 2024
Initiates: Overweight
Price Target: $33
Current: $16.06
Upside: +105.48%
Aug 2, 2024
Maintains: Overweight
Price Target: $500 → $535
Current: $402.49
Upside: +32.92%
Jul 1, 2024
Maintains: Overweight
Price Target: $9 → $7
Current: $2.05
Upside: +241.46%
May 24, 2024
Maintains: Overweight
Price Target: $15
Current: $5.00
Upside: +200.00%
May 3, 2024
Maintains: Neutral
Price Target: $78 → $104
Current: $89.54
Upside: +16.15%
Apr 29, 2024
Initiates: Overweight
Price Target: $42
Current: $7.27
Upside: +477.72%
Mar 8, 2024
Maintains: Overweight
Price Target: $11 → $21
Current: $1.79
Upside: +1,073.18%
Dec 22, 2023
Downgrades: Neutral
Price Target: $27 → $1.5
Current: $0.47
Upside: +217.19%
Oct 25, 2023
Maintains: Overweight
Price Target: $135 → $130
Current: $42.66
Upside: +204.74%
Jun 12, 2023
Maintains: Overweight
Price Target: $22
Current: $8.06
Upside: +172.95%
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $1.87
Upside: +113.90%
May 12, 2023
Maintains: Overweight
Price Target: $26 → $25
Current: $6.34
Upside: +294.32%
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $258.59
Upside: +11.37%
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $33.54
Upside: +22.24%
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $54.62
Upside: -48.74%
Aug 23, 2021
Initiates: Overweight
Price Target: $40
Current: $78.09
Upside: -48.78%
Jul 12, 2021
Initiates: Neutral
Price Target: $90
Current: $4.10
Upside: +2,095.12%
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $1.93
Upside: +4,874.09%